Literature DB >> 15106045

[Outcome of 268 patients with pancreatic carcinoma treated surgically].

M Uravic1, A Depolo, R Dobrilla-Dintinjana, N Petrosic, H Grbas, D Miletic, Z Tomse, Z Kastelan.   

Abstract

From January 1st 1987 to December 31st 2001, 268 patients (pts) with the diagnosis of pancreatic adenocarcinoma had undergone surgery at Surgical Clinic of University Hospital Rijeka. Pts were of both sexes: 154 males (57%) and 114 females (43%). The mean age of pts at the time of operation was 66 +/- 11.4 years. 36 pts (13.4%) underwent curative resection, while 198 pts (73.9%) underwent palliative operation. At 34 pts (12.7%) explorative laparotomy and biopsy were preformed. Overall 30-days postoperative mortality was 12.3% (33 pts). 44 pts (16.4%) developed postoperative complications. Mean overall survival after surgery was 5.8 months. Pts who underwent curative resection survived significantly longer (median 24.2 months) than pts with palliative surgery (median 5.4 months). 8 pts (2.98%) survived more than two years after surgery. Lymph node involvement, distant metastases and postoperative complications were predictors of significantly worse survival.

Entities:  

Mesh:

Year:  2004        PMID: 15106045     DOI: 10.1055/s-2004-818740

Source DB:  PubMed          Journal:  Zentralbl Chir        ISSN: 0044-409X            Impact factor:   0.942


  3 in total

Review 1.  [Vacuum-assisted closure therapy and wound coverage in soft tissue injury. Clinical use].

Authors:  G Holle; G Germann; M Sauerbier; K Riedel; H von Gregory; M Pelzer
Journal:  Unfallchirurg       Date:  2007-04       Impact factor: 1.000

2.  [Discussion of wound treatment using vacuum therapy].

Authors:  C Willy
Journal:  Unfallchirurg       Date:  2009-03       Impact factor: 1.000

Review 3.  [Survival, mortality and quality of life after pylorus-preserving or classical Whipple operation. A systematic review with meta-analysis].

Authors:  C Fitzmaurice; C M Seiler; M W Büchler; M K Diener
Journal:  Chirurg       Date:  2010-05       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.